HYBRID EVENT: You can participate in person at London, UK or Virtually from your home or work.

4th Edition of International Precision Medicine Conference

August 17-19, 2023 | Hybrid Event

August 17-19, 2023 | London, UK
2023 Speakers

Matthias Schwab

Matthias Schwab, Speaker at Precision Medicine Congress
University of Tübingen, Germany
Title: Pharmacogenomics: current status and future directions

Abstract:

The goal of personalized medicine is to provide individualized treatment and to predict the clinical outcome of different treatments in different patients. Pharmacogenomics (PGx) is one of the core elements in personalized medicine. The basic concept is that interindividual variability in drug response is a consequence of multiple factors, including genomics, epigenomics, the environment and patient characteristics, such as gender, age and/or concomitant medication. PGx research has led to fundamental discoveries in the last decade, and a large resource of PGx traits has been generated in which variation in the gene sequence and/or variation in the expression of genes involved in the metabolism, transport and other targets are associated with alterations in drug response. Clinical important cancer drugs related to PGx information are thiopurines, 5-fluorouracil, tamoxifen, irinotecan etc. Very recent efforts deal particularly with the implementation of PGx into clinical practice based on existing guideline recommendations such as CPIC or DPWG. A new generation of technologies commonly named -Omics permits assessment of the entirety of the components of biological systems and produces an explosion of data and a major shift in our concepts of disease. These technologies will likely shape the future of health care. One aspect of these advances is that the data generated documents the uniqueness of each human being with regard to disease risk and treatment response. These developments have reemphasized the concept of personalized medicine.

Biography:

Matthias Schwab is professor and chair of Clinical Pharmacology, and heads the department of Clinical Pharmacology, University of Tuebingen and the Dr Margarete Fischer-Bosch-Institute of Clinical Pharmacology, Stuttgart, Germany. He studied medicine, holds board certifications in Pediatrics and Clinical Pharmacology. He was visiting professor at St Jude Children’s Res. Hosp., Memphis, US. Schwab’s scientific interests focus on personalized medicine and pharmacogenomics (PGx) and the contribution of ADME genes for better understanding of drug response. Special interests lies in the application of Omics-technologies (e.g. genomics, epigenomics, metabonomics). He is involved in programs for the clinical implementation of research findings and acts as principle investigator of academically initiated drug trials. Schwab received numerous awards, and is member of the German National Academy of Sciences Leopoldina, the Academy of Sciences and Literature, Mainz, Germany, and the Academia Europaea. His scientific accomplishments result in > 400 peer reviewed publications and he serves as Editor-in-Chief of Pharmacogenetics & Genomics, Drug Research, and as Section Editor of Genome Medicine.

Watsapp